BVF Inc
- SEC CIK
- 0001056807
- Latest filing
- Aug 14, 2026
Holdings in Q3 2024
Holdings as of Sep 30, 2024, filed Nov 14, 2024. Long positions only; changes compare share counts with Q2 2024.
- Positions
- 55
- −5 vs. Q2 2024
- Portfolio value
- $3.42B
- −$149.7M (−4.2%) vs. Q2 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 21,751,284 | $1.10B | 32.1% | 00.0% | Unchanged | History |
| KYMRKymera Therapeutics, Inc. | COM | 5,161,801 | $244.3M | 7.1% | 00.0% | Unchanged | History |
| RVMDRevolution Medicines, Inc. | COM | 3,478,612 | $157.8M | 4.6% | −2,502,600−41.8% | Reduced | History |
| MIRMMirum Pharmaceuticals, Inc. | COM | 3,075,907 | $120.0M | 3.5% | −1,294,117−29.6% | Reduced | History |
| TYRATyra Biosciences, Inc. | COM | 4,661,194 | $109.6M | 3.2% | 00.0% | Unchanged | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 9,135,893 | $109.1M | 3.2% | 00.0% | Unchanged | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 2,238,986 | $98.3M | 2.9% | −248,776−10.0% | Reduced | History |
| CGEMCullinan Therapeutics, Inc. | COM | 5,750,683 | $96.3M | 2.8% | 00.0% | Unchanged | History |
| XOMAXOMA Royalty Corp | COM NEW | 3,633,743 | $96.2M | 2.8% | 00.0% | Unchanged | History |
| AXSMAxsome Therapeutics, Inc. | COM | 1,046,000 | $94.0M | 2.7% | +91,000+9.5% | Added | History |
| PTGXProtagonist Therapeutics, Inc | COM | 1,850,167 | $83.3M | 2.4% | −1,469,123−44.3% | Reduced | History |
| FDMT4D Molecular Therapeutics, Inc. | COM | 7,382,642 | $79.8M | 2.3% | +3,460,229+88.2% | Added | History |
| ACIUAC Immune SA | SHS | 19,522,436 | $73.8M | 2.2% | +687,500+3.7% | Added | History |
| GHRSGH Research PLC | ORDINARY SHARES | 10,400,158 | $69.6M | 2.0% | 00.0% | Unchanged | History |
| KURAKura Oncology, Inc. | COM | 3,371,761 | $65.9M | 1.9% | −710,276−17.4% | Reduced | History |
| THRDThird Harmonic Bio, Inc. | COM | 4,365,933 | $59.2M | 1.7% | 00.0% | Unchanged | History |
| IONSIonis Pharmaceuticals Inc | COM | 1,451,879 | $58.2M | 1.7% | −1,734,497−54.4% | Reduced | History |
| ZYMEZymeworks Inc. | COM | 4,607,935 | $57.8M | 1.7% | −1,262,065−21.5% | Reduced | History |
| EPIXESSA Pharma Inc. | COM NEW | 8,748,629 | $53.0M | 1.6% | 00.0% | Unchanged | History |
| AGIOAgios Pharmaceuticals, Inc. | COM | 1,190,107 | $52.9M | 1.5% | 00.0% | Unchanged | History |
| CELCCelcuity Inc. | COM | 3,466,000 | $51.7M | 1.5% | 00.0% | Unchanged | History |
| ETNB89bio, Inc. | COM | 6,811,631 | $50.4M | 1.5% | −756,848−10.0% | Reduced | History |
| FHTXFoghorn Therapeutics Inc. | COM | 5,302,000 | $49.4M | 1.4% | 00.0% | Unchanged | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 1,569,422 | $45.2M | 1.3% | 00.0% | Unchanged | History |
| IDYAIDEAYA Biosciences, Inc. | COM | 1,409,993 | $44.7M | 1.3% | +247,687+21.3% | Added | History |
| ANNXAnnexon, Inc. | COM | 7,000,000 | $41.4M | 1.2% | 00.0% | Unchanged | History |
| CGONCG Oncology, Inc. | COM | 994,596 | $37.5M | 1.1% | −1,423,289−58.9% | Reduced | History |
| RPTXRepare Therapeutics Inc. | COM | 10,333,600 | $35.5M | 1.0% | 00.0% | Unchanged | History |
| NAMSNewAmsterdam Pharma Co N.V. | ORDINARY SHARES | 1,521,948 | $25.3M | 0.7% | 00.0% | Unchanged | History |
| XNCRXencor Inc | COM | 850,000 | $17.1M | 0.5% | +850,000 | New | History |
| ELDNEledon Pharmaceuticals, Inc. | COM | 6,293,282 | $15.7M | 0.5% | 00.0% | Unchanged | History |
| TCRXTScan Therapeutics, Inc. | COM | 2,989,474 | $14.9M | 0.4% | 00.0% | Unchanged | History |
| ENGNenGene Therapeutics Inc. | COM | 2,251,037 | $14.9M | 0.4% | 00.0% | Unchanged | History |
| IMUXImmunic, Inc. | COM | 8,902,972 | $14.7M | 0.4% | 00.0% | Unchanged | History |
| ALLKAllakos Inc. | COM | 16,552,417 | $10.8M | 0.3% | 00.0% | Unchanged | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 967,000 | $9.15M | 0.3% | +967,000 | New | History |
| IMAImageneBio, Inc. | COM | 4,769,164 | $8.25M | 0.2% | 00.0% | Unchanged | History |
| CDTXCidara Therapeutics, Inc. | COM NEW | 703,065 | $7.56M | 0.2% | +360,010+104.9% | Added | History |
| CTMXCytomX Therapeutics, Inc. | COM | 5,228,461 | $6.17M | 0.2% | 00.0% | Unchanged | History |
| VIGLVigil Neuroscience, Inc. | COM | 1,813,633 | $6.17M | 0.2% | 00.0% | Unchanged | History |
| VTGNVistagen Therapeutics, Inc. | COM | 2,000,000 | $6.02M | 0.2% | 00.0% | Unchanged | History |
| VSTMVerastem, Inc. | COM NEW | 1,685,219 | $5.04M | 0.1% | 00.0% | Unchanged | History |
| OVIDOvid Therapeutics Inc. | COM | 3,853,818 | $4.55M | 0.1% | 00.0% | Unchanged | History |
| PVLAPalvella Therapeutics, Inc. | COM NEW | 257,626 | $4.31M | 0.1% | 00.0% | Unchanged | History |
| VERVVerve Therapeutics, Inc. | COM | 650,000 | $3.15M | 0.1% | 00.0% | Unchanged | History |
| SABSSAB Biotherapeutics, Inc. | COM NEW | 917,826 | $2.48M | 0.1% | 00.0% | Unchanged | History |
| MOLNMolecular Partners AG | ADS | 443,221 | $2.14M | 0.1% | 00.0% | Unchanged | History |
| ELEVElevation Acquisition Group Inc. | COM | 2,966,836 | $1.78M | 0.1% | +654,636+28.3% | Added | History |
| CBIOCrescent Biopharma, Inc. | COM | 9,544,262 | $1.61M | <0.1% | 00.0% | Unchanged | History |
| IVAInventiva S.A. | ADS | 686,040 | $1.27M | <0.1% | 00.0% | Unchanged | History |
| TENXTenax Therapeutics, Inc. | COM NEW | 339,549 | $1.17M | <0.1% | +339,549 | New | History |
| ENGNWenGene Therapeutics Inc. | *W EXP 10/31/202 | 945,402 | $803.7K | <0.1% | 00.0% | Unchanged | History |
| MTEMMolecular Templates, Inc. | COM NEW | 522,238 | $733.7K | <0.1% | 00.0% | Unchanged | History |
| NLS Pharmaceutics LtdH57830137 | COM NEW | 143,676 | $728.4K | <0.1% | +143,676 | New | – |
| FBRXForte Biosciences, Inc. | COM NEW | 119,282 | $668.0K | <0.1% | 00.0% | UnchangedConverted for a 1-for-25 split | History |
Sold out since Q2 2024 (9)
Positions held at the end of Q2 2024 that are gone from this filing.
| Security | Class | Shares in Q2 2024 | Value in Q2 2024 | % of portfolio in Q2 2024 | History |
|---|---|---|---|---|---|
| MRUSMerus N.V. | COM | 1,279,049 | $75.7M | 2.1% | History |
| Calliditas Therapeutics AB13124Q106 | SPONSERED ADS | 750,000 | $29.2M | 0.8% | – |
| ROIVRoivant Sciences Ltd. | SHS | 2,742,409 | $29.0M | 0.8% | History |
| JANXJanux Therapeutics, Inc. | COM | 441,528 | $18.5M | 0.5% | History |
| VIRXViracta Therapeutics, Inc. | COM | 3,614,662 | $1.97M | 0.1% | History |
| NLS Pharmaceutics LtdH57830103 | SHS | 5,747,126 | $1.25M | <0.1% | – |
| UNCYUnicycive Therapeutics, Inc. | COM | 2,200,000 | $1.10M | <0.1% | History |
| RZLTRezolute, Inc. | COM NEW | 190,815 | $820.5K | <0.1% | History |
| Aslan Pharmaceuticals Ltd04522R200 | SPON ADS NEW | 1,049,999 | $315.0K | <0.1% | – |